Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome a systematic review

Thrombosis and Haemostasis

Volumn 111, Issue 2, 2013, Pages 354-364

  Sciascia, Savino ^a,b   Sanna, Giovanni ^c   Murru, Veronica ^a   Roccatello, Dario ^b   Khamashta, Munther A ^a,c   Bertolaccini, Maria Laura ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF TURIN   (Italy)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Stroke; Venous thrombosis

Indexed keywords

AUTOANTIBODY; PHOSPHATIDYLSERINE; PHOSPHATIDYLSERINE PROTHROMBIN COMPLEX ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTHROMBIN ANTIBODY; UNCLASSIFIED DRUG;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; ASSAY; DEEP VEIN THROMBOSIS; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ANTIPHOSPHOLIPID ANTIBODIES; ANTIPHOSPHOLIPID SYNDROME; STROKE; VENOUS THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL MARKERS; HUMANS; ODDS RATIO; PHOSPHATIDYLSERINES; PREDICTIVE VALUE OF TESTS; PROTHROMBIN; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS;

EID: 84893175081     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-06-0509     Document Type: Article

References (74)

1. Hughes GR. The antiphospholipid syndrome: ten years on. Lancet 1993; 342: 341-344.
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
3. Loeliger L. Prothrombin as a co-factor of the circulating anticoagulant in systemic lupus erythematosus? Thromb Diath Haemorrh 1959; 3: 237-256.
4. Galli M, Barbui T. Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood 1999; 93: 2149-2157.
5. Haj-Yahia S, Sherer Y, Blank M, et al. Anti-prothrombin antibodies cause thrombosis in a novel qualitative ex-vivo animal model. Lupus 2003; 12: 364-369.
6. Bertolaccini ML, Atsumi T, Koike T, et al. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost 2005; 93: 289-297.
7. Bertolaccini ML, Gomez S, Pareja JF, et al. Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis 2005; 64: 1639-1643.
8. Galli M, Luciani D, Bertolini G, et al. Anti-beta 2-glycoprotein I, antiprothrom-bin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-2723.
9. Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-1832.
10. Lowry R. Kappa as a Measure of Concordance in Categorical Sorting. Available at: http://facultyvassaredu/lowry/kappa.html. Accessed May 28, 2013.
11. Wells GA, B Shea, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed May 28, 2013.
12. GRADE Working Group, GRADE profiler. GRADEpro Version. Available at: http://wwwgradeworkinggrouporg/. Accessed April 5, 2013.
13. Horbach DA, Derksen RH, de Groot PG. The presence of anti-beta 2-glycopro-tein I and anti-prothrombin antibodies and their correlations with venous and arterial thrombosis. Ann Med Int 1996; 147 (Suppl 1): 42-43.
14. Pengo V, Biasiolo A, Brocco T, et al. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost 1996; 75: 721-724.
15. Puurunen M, Vaarala O, Julkunen H, et al. Antibodies to phospholipid-binding plasma proteins and occurrence of thrombosis in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1996; 80: 16-22.
16. Forastiero RR, Martinuzzo ME, Cerrato GS, et al. Relationship of anti beta2-gly-coprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost 1997; 78: 1008-1014.
17. Palosuo T, Virtamo J, Haukka J, et al. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men--a nested case-control study. Thromb Haemost 1997; 78: 1178-1182.
18. Bertolaccini ML, Atsumi T, Khamashta MA, et al. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol 1998; 25: 1104-1108.
19. Vaarala O. Antiphospholipid antibodies and myocardial infarction. Lupus 1998; 7 (Suppl 2): S132-134.
20. Martinuzzo ME, Pombo G, Forastiero RR, et al. Lupus anticoagulant, high levels of anticardiolipin, and anti-beta2-glycoprotein I antibodies are associated with chronic thromboembolic pulmonary hypertension. J Rheumatol 1998; 25: 1313-1319.
21. Akimoto T, Akama T, Kono I, et al. Relationship between clinical features and binding domains of anti-prothrombin autoantibodies in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 1999; 8: 761-766.
22. Galli M, Dlott J, Norbis F, et al. Lupus anticoagulants and thrombosis: clinical association of different coagulation and immunologic tests. Thromb Haemost 2000; 84: 1012-1016.
23. Lakos G, Kiss E, Regeczy N, et al. Antiprothrombin and antiannexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases. J Rheumatol 2000; 27: 924-929.
24. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the anti-phospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheuma 2000; 43: 1982-1993.
25. Donohoe S, MacKie IJ, Isenberg D, et al. Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. Br J Haematol 2001; 113: 544-549.
26. Nojima J, Kuratsune H, Suehisa E, et al. Anti-prothrombin antibodies combined with lupus anti-coagulant activity is an essential risk factor for venous throm-boembolism in patients with systemic lupus erythematosus. Br J Haematol 2001; 114: 647-654.
27. Nojima J, Kuratsune H, Suehisa E, et al. Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and an-nexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clinical Chem 2001; 47: 1008-1015.
28. Pasquier E, Amiral J, de Saint Martin L, et al. A cross sectional study of anti-phospholipid-protein antibodies in patients with venous thromboembolism. Thromb Haemost 2001; 86: 538-542.
29. Sands JJ, Nudo SA, Moore KD, et al. Antibodies to prothrombin, factor V, and beta2-glycoprotein I and vascular access thrombosis. ASAIO J 2001; 47: 507-510.
30. Donohoe S. Detection and clinical associations of antiprothrombin antibodies. Am J Med 2001; 110: 229-230.
31. Salcido-Ochoa F, Cabiedes J, Alarcon-Segovia D, et al. Antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary anti-phospholipid syndrome. J Clin Rheumatol 2002; 8: 251-255.
32. Simmelink MJ, De Groot PG, Derksen RH. A study on associations between antiprothrombin antibodies, antiplasminogen antibodies and thrombosis. J Thromb Haemost 2003; 1: 735-739.
33. Previtali S, Barbui T, Galli M. Anti-beta2-glycoprotein I and anti-prothrombin antibodies in antiphospholipid-negative patients with thrombosis: a case control study. Thromb Haemost 2002; 88: 729-732.
34. Musial J, Swadzba J, Motyl A, et al. Clinical significance of antiphospholipid protein antibodies. Receiver operating characteristics plot analysis. J Rheumatol 2003; 30: 723-730.
35. Ishikura K, Wada H, Kamikura Y, et al. High prevalence of anti-prothrombin antibody in patients with deep vein thrombosis. Am J Hematol 2004; 76: 338-342.
36. Koskenmies S, Vaarala O, Widen E, et al. The association of antibodies to car-diolipin, beta 2-glycoprotein I, prothrombin, and oxidized low-density lipopro-tein with thrombosis in 292 patients with familial and sporadic systemic lupus erythematosus. Scand J Rheumatol 2004; 33: 246-252.
37. Zanon E, Saggiorato G, Ramon R, et al. Anti-prothrombin antibodies as a potential risk factor of recurrent venous thromboembolism. Thromb Haemost 2004; 91: 255-258.
38. Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3: 1231-1238.
39. Tsutsumi A, Hayashi T, Chino Y, et al. Significance of antiprothrombin antibodies in patients with systemic lupus erythematosus: clinical evaluation of the antiprothrombin assay and the antiphosphatidylserine/prothrombin assay, and comparison with other antiphospholipid antibody assays. Modern Rheumatol 2006; 16: 158-164.
40. Gould T, Tikly M, Asherson R, et al. Prevalence and clinical correlates of anti-phospholipid antibodies in South Africans with systemic lupus erythematosus. Scand J Rheumatol 2006; 35: 29-34.
41. Bizzaro N, Ghirardello A, Zampieri S, et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost 2007; 5: 1158-1164.
42. Sailer T, Vormittag R, Zoghlami C, et al. The clinical significance of anti-pro-thrombin antibodies for risk assessment of thromboembolism in patients with lupus anticoagulant. Thrombosis Res 2007; 120: 295-302.
43. Bardin N, Alessi MC, Dignat-George F, et al. Does the anti-prothrombin antibodies measurement provide additional information in patients with thrombosis? Immunobiology 2007; 212: 557-565.
44. Szodoray P, Tarr T, Tumpek J, et al. Identification of rare anti-phospholipid/pro-tein co-factor autoantibodies in patients with systemic lupus erythematosus. Autoimmunity 2009; 42: 497-506.
45. Rask O, Hillarp A, Berntorp E, et al. Anti-prothrombin antibodies are associated with thrombosis in children. Thrombosis Res 2010; 125: 19-24.
46. Hoxha A, Ruffatti A, Pittoni M, et al. The clinical significance of autoantibodies directed against prothrombin in primary antiphospholipid syndrome. Clin Chim Acta 2012; 413: 911-913.
47. Horita T, Ichikawa K, Kataoka H, et al. Human monoclonal antibodies against the complex of phosphatidylserine and prothrombin from patients with the antiphospholipid antibodies. Lupus 2007; 16: 509-516.
48. Jaskowski TD, Wilson AR, Hill HR, et al. Autoantibodies against phosphati-dylserine, prothrombin and phosphatidylserine-prothrombin complex: identical or distinct diagnostic tools for antiphospholipid syndrome? Clin Chim Acta 2009; 410: 19-24.
49. Locht H, Wiik A. Prevalence of antibodies against oxidised LDL in a cohort of 163 patients with positive anti-phospholipid antibodies and recent thrombosis. Rheumatol Intern 2006; 26: 416-421.
50. Miesbach W, Matthias T, Scharrer I. Identification of thrombin antibodies in patients with antiphospholipid syndrome. Ann NY Acad Sci 2005; 1050: 250-256.
51. Horbach DA, van Oort E, Tempelman MJ, et al. The prevalence of a non-phos-pholipid-binding form of beta2-glycoprotein I in human plasma--consequences for the development of anti-beta2-glycoprotein I antibodies. Thromb Haemost 1998; 80: 791-797.
52. Nojima J, Iwatani Y, Suehisa E, et al. The presence of anti-phosphatidylserine/pro-thrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus. Haematologica 2006; 91: 699-702.
53. Adams MJ, Palatinus AA, Harvey AM, et al. Impaired control of the tissue factor pathway of blood coagulation in systemic lupus erythematosus. Lupus 2011; 20: 1474-1483.
54. Lee KO, Kim WJ, Na SJ, et al. Clinical significance of anti-annexin V antibody in acute cerebral ischemia. J Neurol Sci 2011; 305: 53-56.
55. Cojocaru IM, Cojocaru M, Popescu AN, et al. Study of antiphospholipid antibodies in type 2 diabetes mellitus with and without diabetic retinopathy. Roman J Internal Med 2009; 47: 267-271.
56. Robertson B, Urquhart C, Ford I, et al. Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies. J Thromb Haemost 2007; 5: 1679-1685.
57. Santamaria A, Oliver A, Borrell M, et al. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 2003; 34: 2387-2391.
58. Chen WH, Kao YF, Lan MY, et al. A perturbation of antithrombin-III and protein C coupling associates with an increase of anti-beta2-glycoprotein I antibody in non-antiphospholipid antibody syndrome cerebral ischemia. Blood Coagul Fibrinolysis 2002; 13: 703-709.
59. Adams MJ, Donohoe S, Mackie IJ, et al. Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome. Br J Haematol 2001; 114: 375-379.
60. Hoxha A, Ruffatti A, Tonello M, et al. Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome. Lupus 2012; 21: 787-789.
61. Okuma H, Kitagawa Y, Ishikawa T, et al. Study of phosphatidylserine-dependent anti-prothrombin antibody in cerebral infarction. Intern Med 2009; 48: 1351-1355.
62. Bertolaccini ML, Atsumi T, Escudero Contreras A, et al. The value of IgA anti-phospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol 2001; 28: 2637-2643.
63. Hasegawa M, Sato S, Yanaba K, et al. Autoantibodies against phosphatidylser-ine-prothrombin complex in patients with systemic sclerosis. Ann Rheum Dis 2004; 63: 1514-1517.
64. Hasegawa M, Fujimoto M, Hayakawa I, et al. Anti-phosphatidylserine-pro-thrombin complex antibodies in patients with localized scleroderma. Clin Exp Rheumatol 2006; 24: 19-24.
65. Nojima J, Kuratsune H, Suehisa E, et al. Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. Clin Chem 2005; 51: 545-552.
66. Nojima J, Kuratsune H, Suehisa E, et al. Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycopro-tein I and anti-phosphatidylserine/prothrombin antibodies--Co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 2004; 91: 967-976.
67. Vlagea AD, Gil A, Cuesta M V, et al. Antiphosphatidylserine/Prothrombin Antibodies (aPS/PT) as Potential Markers of Antiphospholipid Syndrome. Clin Appl Thromb Hemost 2013; 19: 289-296.
68. Inanc M, Donohoe S, Ravirajan CT, et al. Anti-beta2-glycoprotein I, anti-pro-thrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome. Br J Rheu-matol 1998; 37: 1089-1094.
69. Zigon P, Ambrozic A, Cucnik S, et al. Modified phosphatidylserine-dependent antiprothrombin [corrected] ELISA enables identification of patients negative for other antiphospholipid antibodies and also detects low avidity antibodies. Clin Chem Lab Med 2011; 49: 1011-1018.
70. Zigon P, Cucnik S, Ambrozic A, et al. Antibodies to phosphatidylserine/pro-thrombin complex as an additional diagnostic marker of APS? Lupus 2012; 21: 790-792.
71. Pengo V, Denas G, Bison E, et al. Prevalence and significance of anti-prothrom-bin (aPT) antibodies in patients with Lupus Anticoagulant (LA). Thrombosis Res 2010; 126: 150-153.
72. Wahl DG, Guillemin F, de Maistre E, et al. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis. Lupus 1997; 6: 467-473.
73. Wahl DG, Guillemin F, de Maistre E, et al. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998; 7: 15-22.
74. Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353-2358.